Consun Pharmaceutical Group Limited
HKSE: 1681.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Meng An
- Employees
- 3,164
- Headquarters
- Guangzhou, China
- IPO year
- 2013
- Market cap
- HK$12.9B
- Website
- https://www.chinaconsun.com
Loading 1681…
Loading profile data…Frequently asked questions about 1681
What does Consun Pharmaceutical Group Limited (1681.HK) do?
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chron...
Where does 1681.HK trade?
Consun Pharmaceutical Group Limited (1681.HK) trades on the Hong Kong Stock Exchange.
What sector is 1681.HK in?
Consun Pharmaceutical Group Limited (1681.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Consun Pharmaceutical Group Limited?
Meng An is the chief executive officer of Consun Pharmaceutical Group Limited (1681.HK).
Where is Consun Pharmaceutical Group Limited headquartered?
Consun Pharmaceutical Group Limited is headquartered in China.
Does 1681.HK pay a dividend?
Yes — Consun Pharmaceutical Group Limited (1681.HK) paid a trailing twelve-month dividend of HKD 0.63 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 1681.HK go public?
Consun Pharmaceutical Group Limited (1681.HK) completed its initial public offering in 2013.